Recent Updates
Recently added Catalysts

TNX-102 SL (Tonmya)

Phase 3FDA approved 2025

Fibromyalgia | Small Molecules | Musculoskeletal |Tonix Pharmaceuticals Holding Corp.|Trials Updated: Oct 30, 2026

TNX-102 SL (Tonmya) development status

FDA approval Aug 15, 2025
Approval holderTonix
ApplicationNDA219428
Highest phase Phase 3

Label indication TONMYA ® is indicated for treatment of fibromyalgia in adults. TONMYA is indicated for the treatment of fibromyalgia in adults ( 1 ).

TNX-102 SL (Tonmya) target and mechanism

Molecular target5-HT2A/α1/H1/M1
ModalitySmall Molecules

Also known as TNX-102 SL Tablet, TNX-102 SL, Cyclobenzaprine tablets, Cyclobenzaprine, Cyclobenzaprine Tablet, Cyclobenzaprine HCl

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials13
Total Enrollment3,831

FDA Designations

No designations recorded

TNX-102 SL (Tonmya) clinical trials

TNX-102 SL (Tonmya) · 13 trials · 20 indications

Phase 3 7Phase 2/3 1Phase 2 5
NCT05273749A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaFibromyalgia
COMPLETED457 Analytics
NCT04508621A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaFibromyalgia
COMPLETED514 Analytics
NCT04172831A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaFibromyalgia
COMPLETED503 Analytics
NCT03508700A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDPTSD
COMPLETED93 Analytics
NCT02589275A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsPrimary Fibromyalgia
COMPLETED375 Analytics
NCT02436096A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaFibromyalgia
COMPLETED519 Analytics
NCT0201523412-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia PatientsPrimary Fibromyalgia
COMPLETED158 Analytics
PHASE3COMPLETED
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
FibromyalgiaUnlock trial analytics
PHASE3COMPLETED
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
FibromyalgiaUnlock trial analytics
PHASE3COMPLETED
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
FibromyalgiaUnlock trial analytics
PHASE3COMPLETED
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
PTSDUnlock trial analytics
PHASE3COMPLETED
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Primary FibromyalgiaUnlock trial analytics
PHASE3COMPLETED
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
FibromyalgiaUnlock trial analytics
PHASE3COMPLETED
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
Primary FibromyalgiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.
Baseline (Day -7 to Day -1), Week 14

Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.

Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.
14 weeks

Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Incidence of Newly Emergent Adverse Events
40 weeks

Evaluate the incidence of newly emergent adverse events over an additional 40 weeks of treatment with TNX-102 SL 5.6 mg in patients with PTSD who have participated in a double-blinded lead-in study. Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class. Serious AEs and AEs leading to discontinuation of study drug will also be summarized.

Newly Emergent Adverse Events
Up to 3 months from first dose

The number of patients with at least one adverse event which began after the first dose of TNX-102 SL in this open-label extension study.

Proportion of Patients With ≥30% Pain Improvement
Day 1, Week 12

The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.
Up to 12 months

NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).

Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12
Baseline, Week 12

Daily pain scores were assessed using a 24-hour recall response provided by each patient via an interactive voice response system (IVRS) daily telephone diary. Average daily pain was measured using an 11-point (0-10) numerical rating scale (NRS), with higher scores representing worse pain. Jump to control was used to replace missing data in each treatment arm.

Change from Baseline (Visit 2) in the MADRS total score at Week 6.
From Day 1 to Week 6

Change from Baseline (Visit 2) in the MADRS total score at Week 6. Scores range from 0 to 60. Lower scores indicate less depression.

Change in ASD Score
Week 1, 3 after MVC

Individuals are asked to complete the 14-item Acute Stress Disorder Scale (ASDS) self-report inventory where each item is rated on a 5-point scale (0= Not at all; 1= Mildly; 2= Medium; 3= Quite a bit; 4= Very Much) that indexes acute stress disorder (ASD). Range of possible total scores is 0-56, with higher total scores indicating greater acute stress symptoms.

Daily Diary Pain NRS
Week 14

Change from Baseline in the diary Numeric Rating Scale (NRS) weekly average of daily self-reported worst Long COVID pain intensity scores at the Week 14 endpoint. Scores range from 0 to 10 where a higher score means worse outcome.

Newly Treatment Emergent Adverse Events
Week 12

Number of patients with new treatment emergent AEs since completing lead-in study

The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).
Day 1, Week 12

The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.

Secondary Endpoints

Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint
Week 14
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint
Day 1, Week 14
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint
Day 1, Week 14
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TNX-102 SL Tablet, 5.6 mgEXPERIMENTAL1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
Placebo SL TabletPLACEBO_COMPARATOR1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
TNX-102 SL Tablets, 5.6 mgEXPERIMENTAL1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
TNX-102 SL 5.6 mgEXPERIMENTAL2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
TNX-102 SL Tablet 2.8 mgEXPERIMENTAL1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
TNX-102 SL Tablet, 2.8 mgEXPERIMENTAL1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
TNX-102 SLEXPERIMENTAL1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
TNX-102 SL 2.8 mgEXPERIMENTALPatients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
PlaceboPLACEBO_COMPARATORPatients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
Placebo sublingual tabletsPLACEBO_COMPARATORParticipants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.
Cyclobenzaprine HClEXPERIMENTALParticipants will be instructed to take a half dose (equivalent to 1 tablet, 2.8 mg) of Cyclobenzaprine HCl in the ED as part of enrollment procedures. If the time between the first half dose and the planned bedtime of the participant is less than 6 hours, participants will be instructed to take 1 tablet (half dose) the first night at bedtime. If the time between the first half dose and planned bedtime of the participant is greater than or equal to 6 hours, then participants will be instructed to take a full dose (equivalent to 2 tablets) the first night. Over the following 13 days, all participants will be instructed to take a full dose of the study drug at bedtime. Each participant will receive 29 tablets and take either 28 or 29 tablets total for the duration of study participation.
TNX-102 SL, 2.8 mgACTIVE_COMPARATOR1 x TNX-102 SL 2.8mg tablet ("TNX-102 SL") and 1 x placebo tablet ("placebo") to be taken sublingually once daily at bedtime.
TNX-102 SL, 5.6 mgACTIVE_COMPARATOR2 x TNX-102 SL 2.8mg tablets ("TNX-102 SL") to be taken sublingually once daily at bedtime.

Interventions

NameTypeDescription
TNX-102 SL Tablet, 5.6 mgDRUGPatients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL TabletDRUGPatients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
TNX-102 SLDRUGPatients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
TNX-102 SL 5.6 mgDRUGcyclobenzaprine HCl sublingual tablets
TNX-102 SL Tablet 2.8 mgDRUGTNX-102 SL 2.8 mg tablet taken daily at bedtime
TNX-102 SL Tablet, 2.8mgDRUGPatients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
TNX-102 SL 2.8mgDRUGPatients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
PlaceboDRUGPatients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Placebo sublingual tabletDRUGParticipants will take placebo ( 2 x placebo sublingual tablets) daily at bedtime.
Cyclobenzaprine HClDRUGTNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites33

Inclusion Criteria: * The patient is male or female 18 to 65 years of age, inclusive. * The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria) Exclusion Criteria...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Fibromyalgia 10 trials

CompanyTickerTrialsLead PhaseDrugs
Axsome Therapeutics, Inc.AXSM2PHASE3AXS-14
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWNov 10, 2026NCT06636786primaryCompletionDate: changed
LOWNov 10, 2026NCT06636786primaryCompletionDate: changed
LOWNov 10, 2026NCT06636786primaryCompletionDate: changed
LOWOct 30, 2026NCT07621237lastUpdatePostDate: changed
LOWOct 30, 2026NCT07621237lastUpdatePostDate: changed
LOWSep 25, 2026NCT07621237startDate: changed
LOWSep 25, 2026NCT07621237startDate: changed

Frequently asked questions about TNX-102 SL (Tonmya)

What is TNX-102 SL (Tonmya)?

TNX-102 SL, also called Tonmya, is an investigational sublingual tablet formulation of cyclobenzaprine HCl developed by Tonix Pharmaceuticals. It is being studied across several conditions, including fibromyalgia, major depressive episode, PTSD, acute stress reaction, and post-acute sequelae of SARS-CoV-2 infection. It is a small-molecule product given as a daily sublingual tablet.

What does TNX-102 SL target?

TNX-102 SL targets the 5-HT2A, alpha-1 adrenergic, H1 histamine, and M1 muscarinic receptors. Its activity across these receptor classes underlies its development as a centrally acting small molecule. The sublingual formulation is designed to deliver cyclobenzaprine HCl, the active ingredient in the tablet.

Who is developing TNX-102 SL?

TNX-102 SL is being developed by Tonix Pharmaceuticals Holding Corp., which trades under the ticker TNXP. The company is running Phase 2 and Phase 3 studies of the sublingual cyclobenzaprine tablet across its pipeline indications, including fibromyalgia, major depressive episode, PTSD, and long COVID-related multi-site pain.

What phase is TNX-102 SL in?

TNX-102 SL is in Phase 2 development overall, with individual programs at different stages. A Phase 3 trial in fibromyalgia has been completed, and Phase 2 studies in major depressive episode and in acute stress reaction and PTSD are currently recruiting. TNX-102 SL is investigational and is not approved for any indication.

What clinical trials is TNX-102 SL in?

Active TNX-102 SL trials include NCT07621237, a Phase 2 monotherapy study versus placebo in major depressive disorder, and NCT06636786, a Phase 2 study in acute stress reaction and PTSD. Completed studies include NCT05273749, a Phase 3 fibromyalgia trial, and NCT05472090, a Phase 2 trial in multi-site pain associated with long COVID.

Is TNX-102 SL the same as cyclobenzaprine?

TNX-102 SL is a sublingual tablet formulation of cyclobenzaprine HCl, so cyclobenzaprine is its active ingredient. It is also referred to as TNX-102 SL Tablet, TNX-102 SL at 2.8 mg, TNX-102 SL 5.6 mg, and Cyclobenzaprine Tablet. The TNX-102 SL name refers specifically to Tonix's investigational sublingual dosage form.